Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Locally Advanced or Metastatic Pancreatic Cancer

Interventions

DRUG

BEY1107

Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.

COMBINATION_PRODUCT

Gemcitabine

Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.

Trial Locations (1)

RECRUITING

Yonsei University Health System Severance Hospital, Seoul

All Listed Sponsors

lead

BeyondBio Inc.

INDUSTRY